Homologous recombination deficiency (HRD) confers sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy, representing a critical biomarker for precision oncology across multiple malignancies. Current HRD assessment relies on next-generation sequencing of genomic scar signatures, but specialized infrastructure requirements, high costs, and prolonged turnaround times limit widespread adoption. These barriers restrict access to HRD testing, particularly in resource-constrained settings where the majority of cancer patients receive care. Pan-cancer HRD prediction has been shown, but robustness across histologies and institutions, leak-safe evaluation, and backbone-dependent generalization remain incompletely characterized. Here we show that IHGAMP (Integrative Histopathology-Genomic Analysis for Molecular Phenotyping), a computational framework using vision transformer foundation models, predicts HRD status from H TSS-level embedding norm stability across 710 tissue source sites suggested limited site-driven magnitude shifts. Our findings establish that routine histopathology contains morphology associated with HRD that enables moderate, histology-dependent prediction, supporting a potential screening/triage role to prioritize confirmatory molecular testing where appropriate.
Zafar et al. (Sat,) studied this question.